Isoliquiritigenin shows significant anti-ovarian cancer effects with low toxicity as a promising natural candidate for targeted therapy

This review examines the potential of isoliquiritigenin treatment for ovarian cancer. The scope covers anti-ovarian cancer effects as a primary outcome. The authors synthesize findings indicating significant inhibitory effects against the disease. Specific effect sizes and absolute numbers were not reported in the source text. Safety and tolerability were assessed as low toxicity. Adverse events, serious adverse events, and discontinuations were not reported. Follow-up duration was not reported. The study population and setting were not reported. Funding or conflicts of interest were not reported. The authors note that isoliquiritigenin is a promising natural candidate for targeted therapy, reversal of drug resistance, and combination therapy. Practice relevance is highlighted as a potential natural candidate for these specific therapeutic goals. Causality was not reported. The certainty of the findings was not reported. Limitations acknowledged by the authors were not reported. The review does not describe a specific study population or intervention comparator beyond the general treatment exposure.